Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Recipharm, the contract development and manufacturing organisation, has invested USD 450,000 into its Research Triangle Park, North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
Ardelyx, Inc. has announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.
4TEEN4 Pharmaceuticals GmbH announced the closing of a EUR 6.9 million Series A financing round.
Fundraising will support the expansion of Hummingbird Bioscience’s discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics
Bpifrance and Pfizer Ventures co-led international investor syndicate
The company will further develop its high-resolution spinal cord stimulation focal pain therapy and perform clinical studies
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
Since its foundation Cambridge Innovation Capital has attracted £1 billion of investment into Cambridge companies, highlighting its dominant position at the heart of the innovation ecosystem